

1 ***TP53* Variant Clusters Stratify the Li-Fraumeni Spectrum and Reveal an**  
2 **Osteosarcoma-Prone Subgroup**

3  
4 Nicholas W Fischer<sup>1</sup>, Brianne Laverty<sup>1,2</sup>, Noa Alon<sup>1</sup>, Emilie Montellier<sup>3</sup>, Kara N Maxwell<sup>4,5</sup>,  
5 Christian P Kratz<sup>6</sup>, Pierre Hainaut<sup>3</sup>, Ran Kafri<sup>7,8</sup>, David Malkin<sup>1,2,10,11</sup>

6  
7 1 Program in Genetics & Genome Biology, The Hospital for Sick Children, Toronto, Canada

8 2 Department of Medical Biophysics, University of Toronto, Toronto, Canada

9 3 Institute for Advanced Biosciences, Université Grenoble Alpes, Grenoble, France

10 4 Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine at  
11 the University of Pennsylvania, Philadelphia, PA, USA

12 5 Department of Genetics, Perelman School of Medicine at the University of Pennsylvania,  
13 Philadelphia, PA, USA

14 6 Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany

15 7 Department of Molecular Genetics, University of Toronto, Toronto, Canada

16 8 Program in Cell Biology, The Hospital for Sick Children, Toronto, Canada

17 10 Division of Hematology-Oncology, The Hospital for Sick Children, Toronto, Canada

18 11 Department of Pediatrics, The Hospital for Sick Children, Toronto, Canada

19

20

21

22

23

24

25

26

27

28

29

30 **ABSTRACT**

31 Li-Fraumeni syndrome (LFS) has recently been redefined as a ‘spectrum’ cancer predisposition  
32 disorder to reflect its broad phenotypic heterogeneity. The wide functional gradient associated  
33 with different *TP53* variants is thought to contribute to LFS heterogeneity, although it is still  
34 poorly understood and there is an unmet clinical need for risk stratification strategies.  
35 Leveraging p53 mutagenesis dataset, we performed an unsupervised cluster analysis that  
36 revealed five *TP53* variant clusters with unique structural and functional consequences.  
37 Classifying variant carriers according to these clusters stratified cancer onset and survival using  
38 discovery and validation cohorts, and exposed important clinical characteristics to consider for  
39 patient management. In particular, we identified a subgroup of monomeric *TP53* variant  
40 carriers prone to osteosarcoma, along with a cluster associated with less “LFS-like” phenotypes  
41 enriched in carriers with no history of cancer. Our classification of *TP53* variants demonstrates  
42 the existence of a wide *TP53*-heritable cancer susceptibility spectrum and provides a new  
43 framework to delineate carriers toward personalized patient care.

44

45 **Keywords:** Li-Fraumeni Syndrome, Spectrum, p53, phenotypic heterogeneity, cancer  
46 predisposition, cluster analysis, osteosarcoma

47

48

49

50

51

52

53

54

55

56

57

58

59 **INTRODUCTION**

60 Inherited cancer susceptibility in Li-Fraumeni Syndrome (LFS; MIM #151623) was first described  
61 in 1969 based on the observation of several families with a high incidence of rare and diverse  
62 cancer types [1]. Since this initial observation, germline *TP53* mutations were identified as the  
63 underlying cause of LFS [2, 3] and the clinical classification has been adapted by multiple  
64 revised sets of criteria [4-7] to incorporate individuals who do not fit the strict ‘classic LFS’  
65 diagnosis [8]. Recently, LFS was reclassified as a ‘spectrum’ of disease rather than a syndrome  
66 to reflect the heterogeneity that has become increasingly evident through genotype-phenotype  
67 association studies [9]. The LFS spectrum encompasses a highly variable age-of-onset with  
68 nearly 30% affected during childhood, largely unpredictable sites of tumor manifestation, and  
69 inconsistent cancer penetrance. To date, the factors causing this heterogeneity in LFS remain  
70 unclear, although unequal mutant p53 functional consequences have been linked to different  
71 cancer phenotypes [10-12].

72

73 Increased use of DNA sequencing in the clinic has led to the discovery of hundreds of novel  
74 germline variants that span the entire *TP53* gene. Missense mutations leading to single amino  
75 acid changes represent the vast majority of *TP53* variants that are associated with LFS. There  
76 are thousands of possible single amino acid substitutions in p53, and currently, at least 1,703  
77 different germline variants have been linked to individuals with cancer, as catalogued by the  
78 National Cancer Institute’s (NCI) *TP53* Database (<https://tp53.isb-cgc.org>). However, research  
79 efforts have focused on variants at a few “hotspot” residues that account for only 30% of  
80 germline *TP53* missense variants found in patients, leaving the majority largely uncharacterized  
81 and many still considered variants of uncertain significance (VUS). Therefore, it is of great  
82 interest to classify all variants in order to provide more accurate cancer risk assessments with  
83 tailored surveillance strategies and treatment plans.

84

85 Mutagenesis studies are an important clinical tool used to assess *TP53* variant pathogenicity,  
86 however, it is often unclear without substantial clinical evidence that is difficult to obtain from  
87 predominantly rare and infrequent variants. The results from large-scale mutagenesis

88 experiments have demonstrated a broad range of functional consequences associated with  
89 different variants, ranging from near wild-type (WT) p53 capabilities to severe loss-of-function  
90 (LOF) [13-15]. As a multifaceted protein, p53 is composed of several domains containing  
91 complex structured and unstructured regions that enable a myriad of cellular tasks. Primarily  
92 operating as a transcription factor, p53 binds to DNA recognition sequences as a tetramer and  
93 regulates the expression of several thousand target genes to orchestrate cellular responses  
94 centering around DNA-damage repair (DDR) and cell fate decisions [16]. Hence, mutations  
95 arising at different locations of the protein can impart different cellular consequences by  
96 altering its transcriptional activity (TA) as well as its non-TA. Some variant p53 species can also  
97 exert a dominant-negative (DN) effect over WT p53 [17, 18]. This is an important feature  
98 because LFS and heritable *TP53*-related cancer predisposition follows an autosomal dominant  
99 inheritance pattern and most patients are heterozygous carriers who retain one copy of WT  
100 *TP53*. Moreover, mutant p53 LOF can vary under different cellular conditions. For example, the  
101 R337H variant—the most frequently reported germline variant due to a genetic founder event  
102 in Brazil—has a conditional pH-dependent LOF and is associated with the tissue-specific  
103 development of adrenocortical carcinoma (ACC) [19, 20]. Thus, the functional assessments  
104 derived from comprehensive variant library screens conducted in varying cellular contexts  
105 provide clinically relevant measurements of specific p53 activities.

106

107 Here, we incorporated p53 variant library screens using an unsupervised cluster analysis and  
108 uncovered five functionally distinct variant clusters. When applied to germline variant carriers  
109 from the NCI *TP53* Database and a validation dataset, we identified unique cancer patterns and  
110 significant differences between ages at onset and cancer survival. Our variant clustering model  
111 provides a new classification tool for variant interpretation and risk stratification of *TP53*  
112 variant carriers.

113

114

115

116

117

118

## 119 METHODS

120

### 121 Functional datasets and unsupervised cluster analysis

122 We selected saturation mutagenesis cellular functional screens as features for dimensionality  
123 reduction. Giacomelli et al. measured p53 cellular loss-of-function (LOF; nutlin-3 treatment in  
124 p53<sup>NULL</sup> human A549 cells), dominant-negative activity (DN; nutlin-3 treatment in isogenic p53<sup>WT</sup>  
125 A549 cells), and DNA-damage repair (DDR; etoposide treatment of p53<sup>NULL</sup> A549 cells) using  
126 competitive growth assays [14]. Kato et al. measured transcriptional activity (TA) in yeast using  
127 a transcriptional reporter assay [13]. We used the median TA values (8 p53 promoter-specific  
128 elements) normalized to WT p53. Matrix correlation plots comparing scaled data were  
129 generated using *pairplot* in Python's Data Visualization library *Seaborn* using the R package  
130 *reticulate*. Dimensionality reduction was performed using PCA (principal component analysis)  
131 and UMAP (Uniform Manifold Approximation and Projection) with R packages *ggfortify* and  
132 *umap*. The R package *cluster* was used to determine the number of clusters to be generated  
133 (Gap statistic, elbow method, and silhouette score) and k-means clustering. Data was visualized  
134 using the R package *ggplot2*.

135

### 136 Structure/function analysis

137 Rendering of the structure of two p53 core DNA-binding domains bound to DNA (PDB #3EXJ)  
138 was done using PyMOL software. Structural/functional domain annotations for each variant  
139 were obtained from the NCI *TP53* Database. Prediction of intrinsically disordered regions was  
140 conducted using IUPred3 [21].

141

### 142 Clinical datasets, curation, and selection criteria

143 The National Cancer Institute's (NCI) *TP53* Database (version R20; <https://tp53.isb-cgc.org>) is a  
144 repository for germline variant carriers that was used as the discovery cohort (n=3,446) to  
145 evaluate clinical associations. Carriers of multiple variants were removed from the dataset  
146 because the relative contribution of the variants is unknown. In addition, carriers of the R337H  
147 variant (n=291) were removed from the dataset due to a known sampling bias as a founder

148 variant in Brazil. Patients or tumors with no ID were removed to avoid inclusion of duplicates.  
149 The validation dataset (n=458) is a multi-institutional collection of individuals and families  
150 carrying germline *TP53* variants from registries at three cancer centers: in Canada (The Hospital  
151 for Sick Children), the United States (Perelman School of Medicine at the University of  
152 Pennsylvania), and Germany (Hannover Medical School). The cohort from Germany included  
153 only carriers of pathogenic or likely pathogenic variants based on the Fortuno classification [22].  
154 All carriers of protein-truncating variants (frameshift, non-sense, and deletions) were included  
155 as a separate group (FS/NS/DEL) in each analysis.

156

### 157 **Comparisons with non-cancer associated datasets and the Variant Curation Expert Panel** 158 **(VCEP) annotations**

159 We used the Genome Aggregation Database (gnomAD; <https://gnomad.broadinstitute.org/>)  
160 v3.1.2 non-cancer dataset mapped against the canonical transcript (Ensembl transcript ID  
161 ENST00000269305.9) to investigate the prevalence of variants in the general population with  
162 no history of cancer. The Fabulous Ladies Over Seventy (FLOSSIES) Database  
163 (<https://whi.color.com/>) contains germline DNA sequencing from 27 genes (including *TP53*)  
164 collected from 10,000 women over 70 years of age who have never had cancer. We identified  
165 27 *TP53* variants in this dataset and mapped them against the *TP53* clusters. *TP53* variant  
166 clusters were also compared to VCEP annotations, which were obtained from the ClinVar  
167 database (<https://www.ncbi.nlm.nih.gov/clinvar/>).

168

### 169 **Survival analysis**

170 The lifetime survival analysis was performed using clinical data obtained from the NCI *TP53*  
171 Database and the validation dataset. Unaffected carriers were included as censored events. The  
172 10-year cancer survival analysis was determined using age at diagnosis to age at death. Patients  
173 were censored at time of last follow-up if not deceased. The R package *survival* was used to  
174 compute Kaplan-Meier (KM) estimates and hazard ratios, and the *survminer* package was used  
175 to generate KM plots.

176

177 **Statistical analysis**

178 All statistical tests were performed using R or GraphPad Prism (v9). Linear relationships in  
179 matrix correlation plots were assessed using Pearson's correlation coefficient. Kruskal-Wallis  
180 tests were used to determine differences between functional scores, Grantham's distance, and  
181 ages at onset across all groups. Pairwise comparisons were then performed using Mann-  
182 Whitney U tests. Chi-squared tests were used to determine significance across groups for  
183 cancer type comparisons in variant carriers and differences of proline substitutions in clusters.  
184 Subsequently, pairwise comparisons were done using Fisher's exact test. All multiple hypothesis  
185 corrections for pairwise tests were done using the Benjamini-Hochberg adjustment to obtain  
186 the false discovery rate (FDR). KM survival estimates were compared using log-rank tests.  
187 Hazard ratios (HR) with 95% confidence intervals (CIs) were calculated using the Cox  
188 proportional hazards regression analysis.

189

190

191 **RESULTS**

192

193 ***Unsupervised learning identifies five clusters of TP53 variants based on p53 cellular functional***  
194 ***features***

195

196 Various functional features of p53 have been evaluated using *TP53* saturation mutagenesis  
197 screens conducted with different cellular systems and drug treatments. These features include  
198 TA, DN activity, LOF, DDR, and proliferation [13-15]. Each study has independently reported a  
199 wide-ranging functional gradient using separate variant libraries. In a preliminary analysis, we  
200 compared the results of these large-scale assays and observed weak to moderately strong inter-  
201 assay correlations (**Fig. 1a** and **Supplementary Fig. 1a**). We found that the correlations were  
202 influenced by the variant locations by examining the assay results in relation to the resident  
203 functional domains (**Fig. 1a** and **Supplementary Fig. 2a**). Strong correlations were observed  
204 between variants within the DNA-binding domain (DBD), whereas these relationships were  
205 weak or absent for C-terminal domain (CTD) variants. N-terminal domain (NTD) and

206 oligomerization domain (OD) variants had weak to moderate linear relationships when  
207 comparing between LOF, DDR, and TA, but did not exhibit DN activity, which was almost  
208 exclusively found in DBD variants.

209  
210 We employed principal component analysis (PCA) for visualization and dimensionality reduction  
211 of the functional features measured by mutagenesis screens covering the p53 protein. At least  
212 two spatially separated clusters were visible within a clearly disjointed distribution of data  
213 points (**Supplementary Fig. 1b**). Variants located in the same domain demonstrated a tendency  
214 to cluster together, with minimal spatial separation between domains, except for a distinct  
215 subgroup of DBD variants (**Supplementary Fig. 2b**). Notably, each of the cancer-associated  
216 hotspot variants as well as monomeric p53 variants were grouped in close proximity,  
217 respectively (**Supplementary Fig. 2b**). Next, unsupervised k-means clustering was performed  
218 with five predicted clusters (**Fig. 1b**) as determined by the gap statistical method  
219 (**Supplementary Fig. 1c**). To validate this with a non-linear approach, we applied uniform  
220 manifold approximation and projection (UMAP) which demonstrated congruent results to the  
221 PCA with a similar spatial distribution of data points with one clearly isolated cluster of DBD  
222 variants (**Fig. 1c**).

223  
224 ***TP53 variant clusters have distinct signatures affecting different structural and functional***  
225 ***characteristics***

226  
227 By mapping the clusters onto the p53 coding sequence, we identified unique variant signatures  
228 (**Fig. 1d**). First, variants in cluster 1 were found throughout the protein and broadly coincide  
229 with intrinsically disordered regions predicted by the IUPred3 computational method [21] (**Fig.**  
230 **1d** and **Supplementary Fig. 3a**). In contrast, clusters 2 and 3 were centered within the highly  
231 structured DBD. Cluster 3 variants were particularly enriched within helix 2 (H2) of the loop-  
232 sheet-helix motif (L1/S/H2) that binds to the major groove of DNA, whereas variants in cluster 2  
233 were primarily located in regions distal to the DNA contact sites (**Supplementary Fig. 3b, c**).  
234 Cluster 4 variants were distinctively concentrated at the CTD (**Fig. 1d**). Lastly, cluster 5 has a



235 wide variant distribution with three sites of markedly increased variant frequencies located in  
236 structured regions known to impact protein stability (**Fig. 1d**). These three loci were found  
237 within TAD1 (transactivation domain 1), OD, and an NTD hinge region (residues 86-93)  
238 associated with stabilizing the p53 tetramer through its interaction with the DBD [23].  
239 Specifically, the residues affected most frequently in cluster 5 are involved in binding to the  
240 main p53 negative regulator MDM2 (residues F19, W23, and L26) [24], DBD stabilization (W91)  
241 [23], p53 oligomerization (I332, R337, and F341), and transactivation (F19, L22, W23, and L26)  
242 [25]. We found a significant difference between the expected frequency of proline substitutions,  
243 which tend to be more structurally disruptive residues, when comparing between the clusters  
244 ( $p < 0.0001$ , chi-squared test). Cluster 5 contains the most substitutions to/from proline, even  
245 after the removal of the proline-rich region (PRR; residues 60-90) (**Supplementary Fig. 3d**).  
246 Clusters 5 and 3 both contain a higher proportion of substitutions to proline compared to  
247 clusters 1, 2, and 4 (**Supplementary Fig. 3e**).

248

249 Substitutions in each cluster were assessed using Grantham's distance, which predicts the  
250 evolutionary distance between amino acid substitutions, where higher scores are considered  
251 more deleterious. Although cluster 5 contains a higher frequency of proline substitutions,  
252 cluster 3 has the highest overall Grantham score compared to all other variant clusters  
253 ( $p < 0.0001$ , Mann-Whitney U test, **Supplementary Fig. 3f**). Collectively, cluster 3 variants have  
254 the most severe functional consequences in cellular assays, including a high degree of DN  
255 activity (**Fig. 2e-h**). In contrast, cluster 1 variants are hypermorphic and cluster 4 primarily  
256 consists of variants with near-WT functionality. Cluster 2 variants are hypomorphic, exhibiting  
257 partial TA, WT-like DDR, and slight DN potential. Lastly, cluster 5 variants exhibit high LOF and  
258 impaired DDR, however, most variants in this cluster retain TA and lack DN activity.

259

260 ***TP53 variant clusters are clinically relevant and display differing associations with cancer***

261

262 The *TP53* Variant Curation Expert Panel (VCEP) plays an important role in evaluating molecular  
263 and clinical evidence to provide variant interpretations accessible through ClinVar

264 (<https://clinicalgenome.org/affiliation/50013>) [26]. VCEP uses variant functional information,  
265 including the mutagenesis assays used in our variant clustering model, in addition to clinical and  
266 population data to determine variant pathogenicity. However, *TP53* variants can be exceedingly  
267 rare and often lack sufficient clinical evidence to establish a clear association with cancer—  
268 particularly those with reduced penetrance or adult onset [27]. Thus, despite great efforts, only  
269 109 of 2,314 potential missense variants within the gene have undergone evaluation, and still,  
270 24 of these remain VUS. We compared the 109 VCEP annotated variants to our unsupervised  
271 clustering model to examine the clinical relevance of each variant cluster (**Fig. 2a**). A  
272 remarkable division was observed between pathogenic/likely pathogenic (P/LP) and  
273 benign/likely benign (B/LB), with cluster 3 displaying a complete separation for P/LP and cluster  
274 1 for B/LB. Using our strategy, variant interpretations of P/LP and B/LB could be extended to  
275 over 1100 variants classified in clusters 1 and 3. Within clusters 2, 4, and 5, the distribution of  
276 VCEP annotated variants were mixed or contained more VUS. If *TP53* variant pathogenicity is a  
277 gradient resulting in a spectrum of cancer risk, then clusters 2, 4, and 5 may represent  
278 intermediate pathogenicity between B/LB cluster 1 and P/LP cluster 3. Subsequently, we  
279 explored germline sequencing datasets to determine the prevalence of each variant cluster in  
280 individuals with or without a history of cancer (**Supplementary Table 1**). Cancer-associated  
281 germline variants in the NCI *TP53* Database were predominantly classified in cluster 3  
282 (1998/3,113 or 64%) (**Fig. 2b**). Similarly, cluster 3 variants also comprised over 64% of those  
283 identified in a multi-institutional validation dataset (n=458) collected from cancer centers  
284 across Canada, the United States, and Germany (**Fig. 2c**). Non-cancer associated germline  
285 variants from the gnomAD database, representing the general healthy population, were most  
286 often classified in cluster 1 (79/186 or 42.5%) (**Fig. 2d**). Moreover, cluster 1 variants were highly  
287 enriched in healthy older women >70 years (19/27 or 70%) with no history of cancer (FLOSSIES  
288 database) (**Fig. 2e**). Overall, the divergence of variant clusters in germline carriers affected  
289 versus unaffected by cancer and the alignment with VCEP annotations supports the potential  
290 value of our clustering strategy to delineate germline carriers into risk stratified groups.  
291

292 ***Classification of TP53 variant carriers based on clusters reveals unique cancer-type***  
293 ***distributions and an osteosarcoma-prone subgroup***

294  
295 Individuals carrying a pathogenic germline *TP53* variant are affected by a broad range of  
296 cancers during childhood and adulthood. We classified *TP53* variant carriers in the NCI *TP53*  
297 Database based on the five clusters and investigated the cancer-type distributions in each  
298 group. Carriers of protein-truncating variants (frameshift, nonsense, and deletions; FS/NS/DEL)  
299 were included as another variant group. Each group of patients exhibited a diverse range of  
300 cancers (**Fig. 3a**), however, our analysis revealed significant differences (chi-squared test)  
301 between the occurrence of specific cancer types when comparing across all groups  
302 (**Supplementary Table 2**). Strikingly, osteosarcomas occurred at more than twice the frequency  
303 in patients carrying a cluster 5 variant (15.8%; 16/101 patients) compared to all other cluster-  
304 based groups ( $p < 0.0001$ , chi-squared test) (**Fig. 3b** and **Supplementary Table 3**). Pairwise  
305 comparisons determined that the odds of developing osteosarcoma for cluster 5 variant  
306 carriers is significantly higher than in all other cluster-based patient groups, with odds ratios of  
307 (OR)=6.3 versus cluster 1 (95% confidence interval (CI)=2.1-22.8; FDR=0.0015, Fisher's exact  
308 test), OR=4.6 versus cluster 2 (95% CI=2.0-10.6; FDR=0.0015, Fisher's exact test), OR=2.5 versus  
309 cluster 3 (95% CI=1.3-4.4; FDR=0.0092, Fisher's exact test), and OR=14.5 versus cluster 4 (95%  
310 CI=2.2-622; FDR=0.0029, Fisher's exact test) (**Supplementary Table 4**). This association did not  
311 reach significance when comparing cluster 5 to FS/NS/DEL carriers in which the frequency of  
312 osteosarcoma was 9.0% (71/788 patients) (OR=1.9; 95% CI=0.98-3.5; FDR=0.065, Fisher's exact  
313 test). All bone tumors in cluster 5 (n=17) were classified as osteosarcomas with the exception of  
314 one unclassified bone sarcoma (not otherwise specified). Notably, upon analysis of the *TP53*  
315 variants in cluster 5 patients, we found that the majority were located in the OD and known to  
316 abolish oligomerization, resulting in monomeric p53 species (L344P, R337C, R337L, R337P, and  
317 R342P, in 81 of 88 individuals from 20 unrelated families) [12, 28]. For carriers of a monomeric  
318 p53 variant, osteosarcomas represented 16.8% (16/95 patients) of all cancers developed in this  
319 subgroup (**Supplementary Table 3**).

320

321 Next, we observed a greater proportion of colorectal cancers in cluster 1 variant carriers.  
322 Colorectal cancer is considered relatively uncommon in LFS, representing 3.4% (136/3987) of  
323 total cancers in NCI *TP53* Database. However, we found a significant difference between the  
324 patient groups ( $p=0.0007$ , chi-squared test), in which cluster 1 carriers exhibited the highest  
325 frequency of colorectal cancer affecting 9.2% (16/174) of patients (**Fig. 3c** and **Supplementary**  
326 **Table 5**). In addition, we identified a significant difference between the expected frequencies of  
327 the core cancers that are commonly associated with LFS: osteosarcoma, soft tissue sarcomas  
328 (STS), breast tumors, brain tumors, adrenocortical carcinoma (ACC), and leukemia ( $p<0.0001$ ,  
329 chi-squared test) (**Supplementary Table 6**). Interestingly, carriers of cluster 1 variants presented  
330 with considerably fewer LFS core cancers (49.7%) versus all other patient groups which each  
331 totalled approximately 70% LFS core cancers (**Fig. 3d**). The odds of manifesting an LFS core  
332 tumor for cluster 1 carriers was at least 2.1-fold lower than all other groups ( $FDR<0.015$ ,  
333 Fisher's exact test) (**Supplementary Table 4**). Together, these observations of unique tumor  
334 patterns suggest that *TP53* variant structural and functional features can impact cancer  
335 pathogenesis in germline carriers.

336

### 337 ***TP53* variant clusters significantly stratify cancer onset and survival of carriers**

338

339 Carriers of *TP53* variants endure a lifelong high susceptibility to cancer with wide-ranging ages  
340 at onset, and some experience multiple cancers. After separating *TP53* variant carriers into  
341 cluster-based groups, we found significant differences between the ages at diagnosis of cancer  
342 ( $p<0.0001$ , Kruskal-Wallis test) (**Fig. 4a,b**). Cancer diagnoses were significantly earlier in carriers  
343 of clusters 3, 5, and FS/NS/DEL variants when compared to carriers of variants in clusters 1, 2,  
344 and 4, with median age differences of at least 7 years (**Fig. 4a** and **Supplementary Table 7**).  
345 Importantly, our validation cohort demonstrated the same pattern of divergent ages at  
346 diagnosis ( $p<0.0001$ , Kruskal-Wallis test), where cluster 1 carriers exhibited the oldest onset,  
347 while clusters 3, 5, and FS/NS/DEL carriers consistently displayed the earliest onset (**Fig. 4b** and  
348 **Supplementary Table 7**).

349

350 Upon analysis of cancer diagnoses in the NCI *TP53* Database, we noticed a drastic increase in  
351 frequency for cluster 5 carriers around age 30 due to a surge of breast tumor cases (**Fig. 4a**).  
352 Breast tumor onset varied considerably between the groups ( $p < 0.0001$ , Kruskal-Wallis test),  
353 and again, carriers of clusters 3, 5, and FS/NS/DEL variants each had significantly earlier onset  
354 when compared to carriers of variants in clusters 1, 2, and 4 (**Fig. 4c** and **Supplementary Table**  
355 **7**). Furthermore, in our analysis of ACC diagnosis, which is typically within the first few years of  
356 life, we found a significant difference between the patient groups ( $p = 0.0095$ ; Kruskal-Wallis  
357 test). In this case, cluster 4 variant carriers manifested ACC during young adulthood with a  
358 median age at diagnosis of 23 years, whereas all other patient groups experienced early  
359 childhood-onset ACC (**Fig. 4c** and **Supplementary Table 7**).

360  
361 Finally, we investigated whether the *TP53* variant clusters could stratify the cancer survival of  
362 carriers. The Kaplan-Meier plot in **Figure 5a** shows that the lifetime cancer survival between  
363 cluster-based patient groups was significantly different ( $p < 0.0001$ , log-rank test). Recapitulating  
364 the pattern of cancer onset, carriers of variants in clusters 1, 2, and 4 had considerably  
365 prolonged survival (median ages 74, 68, and 68, respectively) when compared to clusters 3, 5,  
366 and FS/NS/DEL carriers (median ages 52, 47, and 54, respectively) (**Supplementary Table 8**).  
367 The validation cohort demonstrated a similar trend in lifetime cancer survival ( $p = 0.039$ , log-  
368 rank test) (**Fig. 5b**). Of note, the differences in observed survival time for cluster 5 when  
369 comparing the NCI *TP53* Database and validation dataset is likely due to monomeric p53  
370 carriers. The validation cohort had only 1 monomeric variant carrier of 5 total cluster 5 carriers  
371 with survival data, whereas cluster 5 in the NCI *TP53* Database was comprised entirely of  
372 monomeric variant carriers ( $n = 45$ ). In addition, the observed shift in lifetime cancer survival  
373 between the NCI and validation datasets can be attributed to differences in data collection. The  
374 NCI *TP53* Database is a historical repository containing multigenerational data which provides  
375 lifelong survival projections. The validation dataset contains current patient records, some of  
376 which are pediatric, with less multigenerational data. As such, the validation cohort has more  
377 unaffected carriers with less lifetime data as compared to the NCI *TP53* Database

378 **(Supplementary Table 9)**, thus contributing to the discrepancy since the risk of death increases  
379 over time.

380

381 In order to obtain adequate sample sizes with complete clinical data to analyze 10-year survival  
382 time after cancer diagnosis, we clustered patients into 2 groups (cluster 1.2 and 2.2) rather than  
383 5 and kept FS/NS/DEL as an additional patient group **(Supplementary Fig. 4)**. In this model,  
384 cluster 1.2 variants displayed greater structural and functional consequences as compared to  
385 cluster 2.2 variants **(Supplementary Figure 4d-g)**. Remarkably, the cancer survival between  
386 these two patient groups along with FS/NS/DEL carriers was significantly different using data  
387 from the NCI *TP53* Database ( $p=0.0027$ , log-rank test) **(Fig. 5c)**. Intriguingly, we observed an  
388 even greater stratification between survival outcomes when using the validation cohort  
389 ( $p=0.0068$ , log-rank test). In both cases, cluster 2.2 variant carriers had significantly extended  
390 cancer survival compared to cluster 1.2 **(Supplementary Table 10)**. The differences in 10-year  
391 survival outcomes when using the NCI versus the validation cohort can be explained by the  
392 differences in cancer types between the datasets. Specifically, the validation cohort contained  
393 more breast tumors and fewer bone tumors when compared to the NCI *TP53* Database  
394 **(Supplementary Table 11)**. Overall, this data suggests that the functionally distinct *TP53* variant  
395 clusters can stratify the cancer onset and survival of germline carriers, representing a promising  
396 risk stratification strategy for patients where there is currently none.

397

## 398 **DISCUSSION**

399

400 The broad phenotypic spectrum related to *TP53* variants necessitates a risk stratification  
401 strategy. Diagnosis of LFS and the understanding of specific cancer risk is still a challenge  
402 because *TP53* variants are often rare with limited clinical evidence to base decisions on. The  
403 population prevalence of pathogenic variants is also unclear for the same reasons. Strikingly,  
404 *TP53* variants leading to protein changes occur in 7.8% of the general population (based on  
405 gnomAD v4.0,  $n=807,162$  individuals; not including WT variant P72R), however most are likely  
406 benign. Current estimates suggest that pathogenic variants are found in 1 in 3555-5476

407 individuals [29]. This number was suggested to be as high as 1 in 400-865 using a less stringent  
408 definition of pathogenicity, although it is now considered an overestimate. Clarity around  
409 variant interpretations will help to avoid misclassification and improve patient management.

410

411 Here, we integrated functional screens using dimensionality reduction to gain a better  
412 understanding of the impact of different p53 variant species on their diverse cellular activities,  
413 including TA, DDR, LOF, and DN activity. Previous models to predict variant pathogenicity  
414 treated it as a binary variable and limited the focus to pathogenic versus benign [30, 31]. These  
415 studies did not examine the clinical effects of variants, whereas our approach has refined the  
416 categorization of pathogenicity and related these findings to clinical features to explore the  
417 spectrum of genetic variants. Using unsupervised clustering we identified 5 distinct *TP53*  
418 variant clusters with unique functional properties and clinical relevance. **Table 1** summarizes  
419 the main structural/functional features and clinical outcomes in each variant cluster, and  
420 **Supplementary Table 12** provides a reference for variant cluster assignments. Comparison of  
421 expert annotated variants with the clusters revealed a B/LB (cluster 1) and a P/LP (cluster 3)  
422 group, as well as three other groups with mixed pathogenicity interpretations or largely VUS  
423 (**Fig. 2a**). Since the majority of variants are not classified by VCEP and remain VUS, we used the  
424 clustering approach to classify all variants and found unique associations to cancer. Cluster 3  
425 contained the most variants linked to cancer, and cluster 1 variants were the most prevalent in  
426 a non-cancer dataset (**Fig. 2b-e**). Moreover, cluster 1 variants were enriched in women >70  
427 years who never had cancer.

428

429 We then tested the clinical impact by grouping carriers according to the clusters using discovery  
430 and validation cancer-associated datasets. Clear distinctions between groups, including  
431 unexpected findings, and consistent patterns emerged throughout our study. Specifically, a  
432 significantly higher frequency of osteosarcoma was discovered among cluster 5 carriers of  
433 monomeric p53 variants (**Fig. 3b**). Cluster 1 variant carriers presented with fewer LFS core  
434 cancers and a greater proportion being colorectal tumors (**Fig. 3c,d**). Furthermore, cancers in  
435 cluster 1 carriers were largely adult-onset and the lifetime survival in this group of patients was

436 considerably extended compared to clusters 3, 5, and FS/NS/DEL groups (Fig 4a,b and Fig. 5a,b).  
437 In contrast, cluster 3 variants, which were primarily DBD variants with DN activity, predisposed  
438 to earlier cancer onset with shorter lifetime survival (Fig. 4 and Fig. 5a,b). Cluster 2 variants  
439 were also mostly DBD variants but without DN activity, comprising a group of variants with  
440 intermediate pathogenicity compared to clusters 3 and 1. Cluster 4 carriers also displayed  
441 intermediate pathogenicity, and were distinguished by the delayed onset of ACC in young  
442 adulthood (Fig. 4d).

443  
444 Taken together, the enrichment of cluster 1 variants in populations with no cancer history and  
445 the milder phenotypes associated with these carriers (i.e. older onset, superior lifetime survival,  
446 and less LFS-like tumor profiles) suggests that cluster 1 variants are B/LB. Their presence in the  
447 NCI *TP53* germline dataset may be a result of sampling bias. In fact, the relatively higher  
448 proportion of colorectal cancer in this variant cluster compared to other clusters reflects the  
449 proportion of worldwide cancer diagnoses that are colorectal cancer (10%) according to the  
450 World Health Organization. Previous work has suggested that multigene panel testing in  
451 colorectal cancer has expanded the mutational analysis of *TP53* to a wider range of patients,  
452 including those who do not meet classic LFS criteria, which can result in sampling bias that  
453 inflates cancer risk estimates [32].

454  
455 A limitation of this study was the smaller sample size of the validation cohort that restricted the  
456 cancer type-specific analyses. Within the validation dataset, patient selection in the German  
457 cohort was more stringent for the inclusion of P/LP variants according to the Fortuno criteria  
458 [22], thus restricting the representation of variants in clusters outside of these criteria. In  
459 addition, the limited availability of clinical information made the analysis of survival after  
460 diagnosis less statistically rigorous when using 5 groups. However, by implementing a 2-cluster  
461 model to investigate 10-year survival, we found a remarkable separation between outcomes  
462 (Fig. 5c,d). In this model, cluster 1.2 variants encompassed the most severe functional  
463 consequences (including DN and monomeric variants) and led to significantly reduced survival  
464 time after diagnosis of cancer (Supplementary Figure 4h and Supplementary Table 10).



465  
466 The current results suggest that a cancer risk continuum related to *TP53* variants extends  
467 beyond the LFS spectrum and can be risk stratified using integrative metrics (Fig. 6). At one end  
468 of the risk continuum, we find that cluster 1 variants retain higher functionality and are  
469 tolerable B/LB variants that were likely ascertained in association with cancer due to sampling  
470 bias (Fig. 2d,e). In contrast, we also identified high-risk variant carriers of clusters 3, 5, and  
471 FS/NS/DEL variants that result in earlier onset and poorer overall survival. The observation of  
472 reduced penetrance in clusters 2 and 4 may be the result of conditional variant pathogenicity  
473 under the influence of genetic or environmental modifying factors. Overall, the variant clusters  
474 provide a comprehensive new classification for variant interpretations and reveal novel risk  
475 factors that can be used to tailor an individual's tumor surveillance plan and set clinical  
476 expectations. Considerations for modifying surveillance protocols according to the *TP53* variant  
477 clusters include (1) greater attention to bone lesions in whole-body MRI images from  
478 monomeric variant carriers; (2) intensive screening (particularly very early-onset breast cancer)  
479 for clusters 3, 5, and FS/NS/DEL carriers; (3) less intensive screening for clusters 2 and 4 carriers;  
480 (4) no screening recommended for cluster 1 carriers. Future development of this approach by  
481 incorporating more innovative mutagenesis screens may lead to even more refined risk  
482 stratification and personalized medicine.

483

#### 484 **ACKNOWLEDGEMENTS**

485 This work is supported in part by a Terry Fox New Frontiers Program Project grant from the  
486 Terry Fox Research Institute (#1084). D.M. holds the CIBC Children's Foundation Chair in Child  
487 Health Research. C.P.K. has been supported by the BMBF ADDRESS (01GM2205A) and by  
488 the Deutsche Kinderkrebsstiftung (DKS2021.25).


489

#### 490 **REFERENCES**


- 491 1. Li, F.P. and J.F. Fraumeni, Jr., *Rhabdomyosarcoma in children: epidemiologic study and*  
492 *identification of a familial cancer syndrome*. J Natl Cancer Inst, 1969. **43**(6): p. 1365-73.  
493 2. Malkin, D., et al., *Germ line p53 mutations in a familial syndrome of breast cancer,*  
494 *sarcomas, and other neoplasms*. Science, 1990. **250**(4985): p. 1233-8.

- 495 3. Srivastava, S., et al., *Germ-line transmission of a mutated p53 gene in a cancer-prone*  
496 *family with Li-Fraumeni syndrome*. Nature, 1990. **348**(6303): p. 747-9.
- 497 4. Birch, J.M., et al., *Prevalence and diversity of constitutional mutations in the p53 gene*  
498 *among 21 Li-Fraumeni families*. Cancer Res, 1994. **54**(5): p. 1298-304.
- 499 5. Eeles, R.A., *Germline mutations in the TP53 gene*. Cancer Surv, 1995. **25**: p. 101-24.
- 500 6. Chompret, A., et al., *Sensitivity and predictive value of criteria for p53 germline mutation*  
501 *screening*. J Med Genet, 2001. **38**(1): p. 43-7.
- 502 7. Tinat, J., et al., *2009 version of the Chompret criteria for Li Fraumeni syndrome*. J Clin  
503 Oncol, 2009. **27**(26): p. e108-9; author reply e110.
- 504 8. Li, F.P., et al., *A cancer family syndrome in twenty-four kindreds*. Cancer Res, 1988.  
505 **48**(18): p. 5358-62.
- 506 9. Kratz, C.P., et al., *Analysis of the Li-Fraumeni Spectrum Based on an International*  
507 *Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53*  
508 *Database Analysis*. JAMA Oncol, 2021. **7**(12): p. 1800-1805.
- 509 10. Kennedy, M.C. and S.W. Lowe, *Mutant p53: it's not all one and the same*. Cell Death  
510 Differ, 2022. **29**(5): p. 983-987.
- 511 11. Sabapathy, K. and D.P. Lane, *Therapeutic targeting of p53: all mutants are equal, but*  
512 *some mutants are more equal than others*. Nat Rev Clin Oncol, 2018. **15**(1): p. 13-30.
- 513 12. Fischer, N.W., et al., *Association Between the Oligomeric Status of p53 and Clinical*  
514 *Outcomes in Li-Fraumeni Syndrome*. J Natl Cancer Inst, 2018. **110**(12): p. 1418-1421.
- 515 13. Kato, S., et al., *Understanding the function-structure and function-mutation relationships*  
516 *of p53 tumor suppressor protein by high-resolution missense mutation analysis*. Proc  
517 Natl Acad Sci U S A, 2003. **100**(14): p. 8424-9.
- 518 14. Giacomelli, A.O., et al., *Mutational processes shape the landscape of TP53 mutations in*  
519 *human cancer*. Nat Genet, 2018. **50**(10): p. 1381-1387.
- 520 15. Kotler, E., et al., *A Systematic p53 Mutation Library Links Differential Functional Impact*  
521 *to Cancer Mutation Pattern and Evolutionary Conservation*. Mol Cell, 2018. **71**(5): p. 873.
- 522 16. Fischer, M., *Census and evaluation of p53 target genes*. Oncogene, 2017. **36**(28): p.  
523 3943-3956.
- 524 17. Willis, A., et al., *Mutant p53 exerts a dominant negative effect by preventing wild-type*  
525 *p53 from binding to the promoter of its target genes*. Oncogene, 2004. **23**(13): p. 2330-8.
- 526 18. Gencel-Augusto, J. and G. Lozano, *p53 tetramerization: at the center of the dominant-*  
527 *negative effect of mutant p53*. Genes Dev, 2020. **34**(17-18): p. 1128-1146.
- 528 19. Pinto, E.M., et al., *Founder effect for the highly prevalent R337H mutation of tumor*  
529 *suppressor p53 in Brazilian patients with adrenocortical tumors*. Arq Bras Endocrinol  
530 Metabol, 2004. **48**(5): p. 647-50.
- 531 20. DiGiammarino, E.L., et al., *A novel mechanism of tumorigenesis involving pH-dependent*  
532 *destabilization of a mutant p53 tetramer*. Nat Struct Biol, 2002. **9**(1): p. 12-6.
- 533 21. Erdos, G., M. Pajkos, and Z. Dosztanyi, *IUPred3: prediction of protein disorder enhanced*  
534 *with unambiguous experimental annotation and visualization of evolutionary*  
535 *conservation*. Nucleic Acids Res, 2021. **49**(W1): p. W297-W303.
- 536 22. Fortunato, C., et al., *An updated quantitative model to classify missense variants in the*  
537 *TP53 gene: A novel multifactorial strategy*. Hum Mutat, 2021. **42**(10): p. 1351-1361.


- 538 23. Natan, E., et al., *Interaction of the p53 DNA-binding domain with its n-terminal extension*  
539 *modulates the stability of the p53 tetramer*. J Mol Biol, 2011. **409**(3): p. 358-68.
- 540 24. Kussie, P.H., et al., *Structure of the MDM2 oncoprotein bound to the p53 tumor*  
541 *suppressor transactivation domain*. Science, 1996. **274**(5289): p. 948-53.
- 542 25. Raj, N. and L.D. Attardi, *The Transactivation Domains of the p53 Protein*. Cold Spring  
543 Harb Perspect Med, 2017. **7**(1).
- 544 26. Fortuno, C., et al., *Specifications of the ACMG/AMP variant interpretation guidelines for*  
545 *germline TP53 variants*. Hum Mutat, 2021. **42**(3): p. 223-236.
- 546 27. Fischer, N.W., Y.V. Ma, and J. Garipey, *Emerging insights into ethnic-specific TP53*  
547 *germline variants*. J Natl Cancer Inst, 2023. **115**(10): p. 1145-1156.
- 548 28. Kawaguchi, T., et al., *The relationship among p53 oligomer formation, structure and*  
549 *transcriptional activity using a comprehensive missense mutation library*. Oncogene,  
550 2005. **24**(46): p. 6976-81.
- 551 29. de Andrade, K.C., et al., *Higher-than-expected population prevalence of potentially*  
552 *pathogenic germline TP53 variants in individuals unselected for cancer history*. Hum  
553 Mutat, 2017. **38**(12): p. 1723-1730.
- 554 30. Carbonnier, V., et al., *Comprehensive assessment of TP53 loss of function using multiple*  
555 *combinatorial mutagenesis libraries*. Sci Rep, 2020. **10**(1): p. 20368.
- 556 31. Ben-Cohen, G., et al., *TP53\_PROF: a machine learning model to predict impact of*  
557 *missense mutations in TP53*. Brief Bioinform, 2022. **23**(2).
- 558 32. Terradas, M., et al., *TP53, a gene for colorectal cancer predisposition in the absence of*  
559 *Li-Fraumeni-associated phenotypes*. Gut, 2021. **70**(6): p. 1139-1146.
- 560




**Figure 1.** Unsupervised cluster analysis of *TP53* missense variants based on cellular p53 functional features. **(a)** Matrix correlation plots comparing functional datasets from p53 mutagenesis datasets covering the entire protein (LOF = loss-of-function; DDR = DNA damage repair; DN = dominant negative activity; TA = transcriptional activity). Variants are colour-coded based on the functional domain they reside in (NTD = N-terminal domain; PRR = proline-rich region; DBD = DNA-binding domain; OD = oligomerization domain; CTD = C-terminal domain). **(b)** Principal component analysis (PCA) and unsupervised k-means clustering performed with p53 mutagenesis cellular functional assay measurements. **(c)** Uniform manifold approximation and projection (UMAP) performed using p53 mutagenesis cellular functional assay measurements and colour-coded based on PCA k-means clustering (N=200, D=0.4). **(d)** Heatmap displaying the codon frequencies and distributions of *TP53* variant clusters. Red arrowheads indicate mutational hotspots in cluster 5. **(e-h)** Violin plots displaying the functional consequences of variants within each cluster (dotted line represents wild-type p53). P-values on plots were calculated using Kruskal-Wallis tests. Mann-Whitney U tests were used for pairwise comparisons (\*\*\*\*p<0.0001).




**Figure 2.** Alignment of *TP53* clusters with the Variant Curation Expert Panel (VCEP) annotations and the representation of clusters across populations with and without cancer. **(a)** Stacked bar plot showing VCEP annotated variants ( $n=109$ ) applied to the variant clusters. **(b)** Bar charts displaying the frequencies of germline variants in each cluster found in the NCI *TP53* Database ( $n=3,113$ ), **(c)** a multi-institutional validation cohort ( $n=458$ ), **(d)** gnomAD non-cancer dataset ( $n=186$ ), and **(e)** FLOSSIES database ( $n=27$ ). P-values on plots were calculated using chi-square tests.



**Figure 3.** Cancer spectrums in germline *TP53* variant carriers classified based on the variant clusters. **(a)** Stacked bar plot displaying the cancer type distribution patterns manifested in germline *TP53* mutation carriers. **(b)** Bar charts showing the frequency of osteosarcoma, **(c)** colorectal cancer, **(d)** and LFS-core cancer types according to the cluster-based patient classification. P-values on plots were calculated using chi-square tests. Fisher's exact tests were used for pairwise comparisons (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ).



**Figure 4.** Age at cancer diagnosis in germline *TP53* variant carriers. **(a)** Line plot displaying the cumulative cancer diagnosis ages over time and a box and whiskers plot (10-90<sup>th</sup> percentiles) representing the ages at cancer diagnosis in the NCI *TP53* Database, and **(b)** in the validation cohort. \*compared to clusters 1, 2, and 4. **(c)** Line plot displaying the frequency of breast tumor diagnosis over time and a box and whiskers plot (10-90<sup>th</sup> percentiles) representing the ages at cancer diagnosis. \*compared to clusters 1, 2, and 4. **(d)** Line plot displaying the frequency of ACC diagnosis over time and box and whiskers plot (10-90<sup>th</sup> percentiles) representing the age at ACC onset. \*compared to clusters 2, 3, and FS/NS/DEL. P-values on plots were calculated using Kruskal-Wallis tests. Mann-Whitney U tests were used for pairwise comparisons (\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ).



**Figure 5.** Survival analysis of *TP53* variant carriers. **(a)** Kaplan-Meier plots displaying the lifetime cancer survival of *TP53* variant carriers from the NCI *TP53* Database and **(b)** a validation cohort, stratified based on the variant clusters. **(c)** Kaplan-Meier plots showing 10-year survival time (age at cancer diagnosis to age at death) of *TP53* variant carriers from the NCI *TP53* Database and **(d)** a validation cohort, based on the 2-cluster model. p-values were calculated using the log-rank test.





- |  |  |
|--|--|
| <p><b>1</b> BENIGN/LIKELY BENIGN:<br/>LOWER RISK</p> <p><b>2</b> HYPOMORPHIC:<br/>INTERMEDIATE RISK</p> <p><b>3</b> DOMINANT-NEGATIVE:<br/>HIGH RISK</p> | <p><b>4</b> LIKELY BENIGN/CONDITIONALLY<br/>PATHOGENIC: LOWER RISK</p> <p><b>5</b> MONOMERIC: HIGH RISK<br/>OTHER: UNCERTAIN RISK</p> <p><b>T</b> TRUNCATING (FS/NS/DEL):<br/>HIGH RISK</p> <p><b>WT</b> WILD-TYPE</p> |
|--|--|

**Figure 6.** Interpretation of *TP53* variant clusters as a cancer susceptibility continuum based on cellular functional and clinical evidence.

Variant Group	Structural Features and Regions	Functional Features	Defining Cancer Phenotypes	Cancer onset (median age in years with 95% CI)	Lifetime cancer survival (median age in years with 95% CI)
Cluster 1	Disordered regions	Hypermorphic	Late onset/Less LFS core cancers	42 (37-46)	74 (69-NA)
Cluster 2	DBD non-contact sites	Hypomorphic	–	39 (35-41)	68 (63-80)
Cluster 3	DBD contact sites	LOF/DN	Very early onset breast cancer	29 (28-30)	52 (49-54)
Cluster 4	CTD	WT-like function	Young adult ACC onset	37 (31-47)	68 (63-NA)
Cluster 5	OD (monomeric) /TAD1/NTD hinge region	LOF/Hypomorphic	Osteosarcoma/Very early onset breast cancer*	30 (28-33)	47 (33-NA)*
FS/NS/DEL	Protein truncating	LOF	Very early onset breast cancer	28 (27-30)	54 (47-NA)

**Table 1.** Summary of structural/functional features and clinical phenotypes associated with *TP53* variant clusters.

\*Data from monomeric variant carriers